Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes.

The most active factor VIIa (FVIIa) variants identified to date carry concurrent substitutions at positions 158, 296 and 298 with the intention of generating a thrombin-mimicking motif, optionally combined with additional replacements within the protease domain [Persson, E., Kjalke, M. & Olsen, O. H. (2001) Proc. Natl Acad. Sci. USA98, 13583-13588]. Here we have characterized variants of FVIIa mutated at one or two of these positions to assess the relative importance of the individual replacements. The E296V and M298Q mutations gave an increased intrinsic amidolytic activity (about two- and 3.5-fold, respectively) compared with wild-type FVIIa. An additive effect was observed upon their combination, resulting in the amidolytic activity of E296V/M298Q-FVIIa being close to that of the triple mutant. The level of amidolytic activity of a variant was correlated with the rate of inhibition by antithrombin (AT). Compared with wild-type FVIIa, the Ca2+ dependence of the intrinsic amidolytic activity was significantly attenuated upon introduction of the E296V mutation, but the effect was most pronounced in the triple mutant. Enhancement of the proteolytic activity requires substitution of Gln for Met298. The simultaneous presence of the V158D, E296V and M298Q mutations gives the highest intrinsic activity and is essential to achieve a dramatically higher relative increase in the proteolytic activity than that in the amidolytic activity. The N-terminal Ile153 is most efficiently buried in V158D/E296V/M298Q-FVIIa, but is less available for chemical modification also in the presence of the E296V or M298Q mutation alone. In summary, E296V and M298Q enhance the amidolytic activity and facilitate salt bridge formation between the N-terminus and Asp343, E296V reduces the Ca2+ dependence, M298Q is required for increased factor X (FX) activation, and the simultaneous presence of the V158D, E296V and M298Q mutations gives the most profound effect on all these parameters.

[1]  W. Ruf,et al.  Role of zymogenicity-determining residues of coagulation factor VII/VIIa in cofactor interaction and macromolecular substrate recognition. , 2002, Biochemistry.

[2]  S. Bajaj,et al.  The N-terminal Epidermal Growth Factor-like Domain in Factor IX and Factor X Represents an Important Recognition Motif for Binding to Tissue Factor* , 2002, The Journal of Biological Chemistry.

[3]  Lalith E. Perera,et al.  Predicted solution structure of zymogen human coagulation FVII , 2002, J. Comput. Chem..

[4]  O. Olsen,et al.  Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  O. Olsen,et al.  Substitution of Valine for Leucine 305 in Factor VIIa Increases the Intrinsic Enzymatic Activity* , 2001, The Journal of Biological Chemistry.

[6]  M. Ultsch,et al.  The factor VII zymogen structure reveals reregistration of beta strands during activation. , 2001, Structure.

[7]  W Ruf,et al.  Residue Met156 Contributes to the Labile Enzyme Conformation of Coagulation Factor VIIa* , 2001, The Journal of Biological Chemistry.

[8]  O. Olsen,et al.  Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor. , 2001, Biochemistry.

[9]  R. Kelley,et al.  The tissue factor region that interacts with substrates factor IX and Factor X. , 2000, Biochemistry.

[10]  M. Dwyer,et al.  Peptide exosite inhibitors of factor VIIa as anticoagulants , 2000, Nature.

[11]  K. Harlos,et al.  Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla). , 1999, Journal of structural biology.

[12]  A M Brzozowski,et al.  Structure of human factor VIIa and its implications for the triggering of blood coagulation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. St Charles,et al.  Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. , 1999, Journal of molecular biology.

[14]  W. Ruf,et al.  Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor* , 1997, The Journal of Biological Chemistry.

[15]  W. Bode,et al.  Comparative Analysis of Haemostatic Proteinases: Structural Aspects of Thrombin, Factor Xa, Factor IXa and Protein C , 1997, Thrombosis and Haemostasis.

[16]  W. Ruf,et al.  Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Neuenschwander,et al.  The Location of the Active Site of Blood Coagulation Factor VIIa above the Membrane Surface and Its Reorientation upon Association with Tissue Factor , 1996, The Journal of Biological Chemistry.

[18]  P. Neuenschwander,et al.  Substrate Recognition by Tissue Factor-Factor VIIa , 1996, The Journal of Biological Chemistry.

[19]  O. Olsen,et al.  Structural changes in factor VIIa induced by Ca2+ and tissue factor studied using circular dichroism spectroscopy , 1996, Protein science : a publication of the Protein Society.

[20]  E. Persson,et al.  Site‐directed mutagenesis but not γ‐carboxylation of Glu‐35 in factor VIIa affects the association with tissue factor , 1996, FEBS letters.

[21]  David W. Banner,et al.  The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor , 1996, Nature.

[22]  L. Petersen,et al.  Structurally and functionally distinct Ca2+ binding sites in the gamma-carboxyglutamic acid-containing domain of factor VIIa. , 1995, European journal of biochemistry.

[23]  W. Ruf Factor VIIa residue Arg290 is required for efficient activation of the macromolecular substrate factor X. , 1994, Biochemistry.

[24]  K. Mann,et al.  Cooperative interaction of divalent metal ions, substrate, and tissue factor with factor VIIa. , 1994, Biochemistry.

[25]  J. Birktoft,et al.  Identification of a calcium binding site in the protease domain of human blood coagulation factor VII: evidence for its role in factor VII-tissue factor interaction. , 1993, Biochemistry.

[26]  K. Norris,et al.  Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. , 1990, The Journal of biological chemistry.

[27]  L. Thim,et al.  Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. , 1988, Biochemistry.